Is the official price of Apelvis-Piqray in India cheap?
Alpelisib (Alpelisib)-Piqray is a targeted therapy drug mainly used to treat HR-positive, HER2-negative breast cancer, especially for advanced or metastatic patients who have progressed after receiving endocrine therapy. The mechanism of action of Apelvis is to interfere with the growth and survival of tumor cells by selectively inhibiting the PI3K (phosphatidylinositol-3-kinase) pathway, thereby achieving anti-tumor effects. The PI3K pathway plays a key role in a variety of cancers, so targeted therapy for this pathway is of great significance.
In clinical trials, Apelvis was shown to significantly improve progression-free survival (PFS) when used in combination with endocrine therapies such as letrozole or exemestane. This makes Apelvis a promising treatment option, especially in patients who do not respond well to traditional treatments.

Regarding the market price of Apelix, the Indian version of Apelvis (brand namePiqray) is a genuine drug produced by the Swiss pharmaceutical company Novartis. Although there is no difference in ingredients between it and the European version of the original drug, the pricing strategy is different due to regional differences. Currently, the price of the Indian version per box (150mg*28 tablets) is approximately more than 3,000 yuan, and the specific price may change due to exchange rate fluctuations. This price is indeed much cheaper than similar drugs in other countries, making it more affordable for more patients.
It should be noted that although there are currently no generic versions of Apelvis available in India, due to its relatively low price, patients may consider the Indian version as a viable option when choosing treatment. This means that for those patients with limited financial resources, it means a greater possibility of obtaining effective treatment. At the same time, the Indian market has relatively loose regulations on pharmaceuticals, which has also contributed to lower prices of genuine drugs.
Reference materials:https://www.piqray.com/
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)